# US 2003/0216363 A1 · Method of treating hyperlipidemic and hyperglycemic conditions in mammals using pregnadienols and pregnadienones

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0216363 A1
- Document ID: US20030216363A1
- Status: Published application
- Kind: A1
- Application number: 10/385,936
- Filed: 2003-03-14
- Published: 2003-11-20
- Earliest claimed: 1999-01-12
- Assignees: Council of Scientific and Industrial Research
- Inventors: Ram Pratap; Ram Chandra Gupta; Ramesh Chander; Ashok Kumar Khanna; Arvind Kumar Srivastava; Deepak Raina; Satyavan Singh; Savita Srivastava; Anil Kumar Rastogi; Omkar Prasad Asthana; Swarn Nityanand; Nitya Anand; Ashim Ghatak; Narinder Kumar Kapoor; Sukh Dev
- Web page: https://patentgrep.com/patent/US20030216363A1

## CPC

- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07J 13/005: {with double bond in position 16 (17)}
- C07J 13/007: {with double bond in position 17 (20)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07J: STEROIDS (seco-steroids C07C)

## Abstract

The invention provides a method of using pregnadienones and pregnadienols represented by the structural formula (I) as shown herein below 1 Wherein X═OH or O or combination thereof and positioning of olefinic bonds are at 4(5); 5(6); 6(17); 17(20) or various combinations and said compounds containing at least one olefinic bond in or on their D-ring for the treatment of hypolipidemic and hypoglycemic conditions in mammals, said method comprising administering an effective amount of the said compounds to the recipient mammals.

## Claims

### Claim 1

A method of using compounds represented by the structural formula (I) as shown in the accompanying drawings, containing at least one olefinic bond in or on their D-ring for the treatment of hypolipidemic and hypoglycemic conditions in mammals, said method comprising administering an effective amount of the said compounds to recipient mammals.

### Claim 2 (depends on 1)

A method as claimed in claim 1, wherein the compounds of formula (I) are administered in the form of tablets, capsules or injectibles.

### Claim 3 (depends on 1)

A method as claimed in claim 1, wherein the compounds of formula (I) are characterised as pregnadienones and pregnadienols.

### Claim 4 (depends on 1)

A method as claimed in claim 1, wherein the most preferred compound belonging to the family of preganienones and pregnadienols represented by formula (I) is 3β-hydroxy-pregna-5,16-dien-20-one, which is represented by the structural formula (II) as shown in the accompanying drawings.

### Claim 5 (depends on 1)

A method as claimed in claim 1, wherein the compounds of formula (I) are optionally administered to the recipient mammal as an admixture with conventional anti-platelet, anti artherosclerotic, hypolipoproteinic and antidiabetic drugs.

### Claim 6 (depends on 1)

A method as claimed in claim 1 wherein the compounds of formula (I) are essentially free of side effects associated with conventional hypolipidemic and hypoglycemic drugs.

### Claim 7 (depends on 1)

A method as claimed in claim 1, wherein the compounds of formula (I) exhibit cardioprotective, anti-diabetic, anti-artherosclerotic and anti-oxidant properties.

### Claim 8

A method of treatment of hypolipidemic and hypoglycemic conditions in mammals, which comprises administration to a recipient, a therapeutic composition comprising an effective amount of compound of formula (I) with conventional carriers.

### Claim 9 (depends on 8)

A method of treatment as claimed in claim 8, wherein the recipient mammals are selected from the group comprising rats, human beings, rhesus monkeys and rabbits.

### Claim 10 (depends on 8)

A method of treatment as claimed in claim 8, wherein the conventional carriers are selected from anti-platelet, anti-artherosclerotic, hypolipoproteinic and anti-diabetic drugs.

### Claim 11 (depends on 8)

A method of treatment as claimed in claim 8 wherein the said compounds of formula (I) essentially contain an olefinic bond in or on their D-ring.

### Claim 12 (depends on 8)

A method of treatment as claimed in claim 8 wherein the compounds of formula (I) are essentially free of androgenic, progestinal and side effects.

### Claim 13 (depends on 8)

A method of treatment as claimed in claim 8 wherein the therapeutic composition is administered in the form of tablets, capsules and injectibles.
